KALV
Kalvista Pharmaceuticals Inc
NASDAQ: KALV · HEALTHCARE · BIOTECHNOLOGY
$26.76
+0.04% today
Updated 2026-06-03
Market cap
$1.44B
P/E ratio
—
P/S ratio
12.55x
EPS (TTM)
$-3.94
Dividend yield
—
52W range
$10 – $27
Volume
4.0M
Kalvista Pharmaceuticals Inc (KALV) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$26.76
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -118.70%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.